Yes, PKM2 is considered a promising therapeutic target in cancer treatment. Strategies to modulate PKM2 activity include small molecule inhibitors, activators, and RNA interference techniques. Inhibiting PKM2 could potentially disrupt the metabolic flexibility of cancer cells, leading to reduced proliferation and increased apoptosis. Conversely, forcing PKM2 into its active tetrameric form could also impair the anabolic pathways necessary for tumor growth.
